Media headlines about Trupanion (NASDAQ:TRUP) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Trupanion earned a coverage optimism score of 0.24 on Accern’s scale. Accern also assigned media headlines about the financial services provider an impact score of 45.7902063102422 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- CL King Downgrades Trupanion, Inc. (TRUP) to Neutral – StreetInsider.com (streetinsider.com)
- Trupanion, Inc. (TRUP) Insider Asher Bearman Sells 4,039 Shares (americanbankingnews.com)
- Trupanion : Veterinarians see the value of medical insurance firsthand with their own pets (4-traders.com)
- Reviewing Trupanion (TRUP) and Health Insurance Innovations (HIIQ) (americanbankingnews.com)
- Trupanion, Inc., (NASDAQ: TRUP), 8×8, Inc., (NASDAQ: EGHT), KapStone Paper and Packaging Corporation, (NYSE … – Stocks In The News (press release) (tradingnewsnow.com)
Shares of Trupanion (NASDAQ:TRUP) opened at $29.55 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.87 and a quick ratio of 1.87. Trupanion has a 12-month low of $13.71 and a 12-month high of $33.00.
A number of analysts have recently commented on the company. Canaccord Genuity upped their price objective on Trupanion from $28.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, August 2nd. BidaskClub downgraded Trupanion from a “hold” rating to a “sell” rating in a report on Thursday, September 7th. CL King started coverage on Trupanion in a report on Tuesday. They set a “neutral” rating for the company. Stifel Nicolaus reaffirmed a “buy” rating and set a $24.00 price target (up from $18.00) on shares of Trupanion in a research report on Wednesday, August 2nd. Finally, Royal Bank Of Canada upped their price target on shares of Trupanion from $19.00 to $26.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 2nd. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Trupanion currently has an average rating of “Buy” and a consensus price target of $28.83.
In other Trupanion news, insider Asher Bearman sold 2,500 shares of the company’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $22.55, for a total value of $56,375.00. Following the completion of the transaction, the insider now directly owns 5,539 shares of the company’s stock, valued at approximately $124,904.45. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Darryl Rawlings sold 3,500 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $21.13, for a total transaction of $73,955.00. Following the completion of the transaction, the insider now directly owns 1,449,505 shares of the company’s stock, valued at $30,628,040.65. The disclosure for this sale can be found here. Over the last three months, insiders sold 117,539 shares of company stock valued at $3,043,693. 31.24% of the stock is currently owned by corporate insiders.
Trupanion Company Profile
Trupanion, Inc provides medical insurance plans for cats and dogs throughout the United States, Canada and Puerto Rico. The Company operates in two business segments: subscription business and other business. The subscription business segment includes monthly subscriptions for its medical plan, which are marketed to consumers.
What are top analysts saying about Trupanion Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Trupanion Inc. and related companies.